PharmaCyte Biotech and UTS to Partner on Diabetes Treatment
PharmaCyte Biotech will partner with the University of Technology Sydney (UTS) to co-develop the company’s preclinical treatment for insulin-dependent diabetes that uses its Cell-in-a-Box® technology. The value of the collaboration was not disclosed. The diabetes treatment consists of Melligen cells—human
Read more →